The Technology Co.,Ltd.

KOSDAQ:A043090 Stock Report

Market Cap: ₩7.4b

TechnologyLtd Past Earnings Performance

Past criteria checks 0/6

TechnologyLtd's earnings have been declining at an average annual rate of -31.1%, while the Life Sciences industry saw earnings growing at 31.2% annually. Revenues have been growing at an average rate of 45.3% per year.

Key information

-31.1%

Earnings growth rate

-10.6%

EPS growth rate

Life Sciences Industry Growth53.7%
Revenue growth rate45.3%
Return on equity-41.4%
Net Margin-109.1%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Investors Give The Technology Co.,Ltd. (KOSDAQ:043090) Shares A 36% Hiding

Oct 30
Investors Give The Technology Co.,Ltd. (KOSDAQ:043090) Shares A 36% Hiding

Is TechnologyLtd (KOSDAQ:043090) A Risky Investment?

Oct 21
Is TechnologyLtd (KOSDAQ:043090) A Risky Investment?

Slammed 27% The Technology Co.,Ltd. (KOSDAQ:043090) Screens Well Here But There Might Be A Catch

Jul 24
Slammed 27% The Technology Co.,Ltd. (KOSDAQ:043090) Screens Well Here But There Might Be A Catch

Is TechnologyLtd (KOSDAQ:043090) Using Too Much Debt?

Jul 22
Is TechnologyLtd (KOSDAQ:043090) Using Too Much Debt?

Potential Upside For The Technology Co.,Ltd. (KOSDAQ:043090) Not Without Risk

May 22
Potential Upside For The Technology Co.,Ltd. (KOSDAQ:043090) Not Without Risk

Would Exergy21 (KOSDAQ:043090) Be Better Off With Less Debt?

Feb 28
Would Exergy21 (KOSDAQ:043090) Be Better Off With Less Debt?

Revenue & Expenses Breakdown

How TechnologyLtd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A043090 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2415,746-17,17612,4750
31 Mar 2417,408-24,97919,6280
31 Dec 2315,895-27,11119,4090
30 Sep 2311,183-22,16415,6370
30 Jun 236,739-19,82513,5470
31 Mar 233,365-10,7325,6720
31 Dec 223,897-3,3415,1010
30 Sep 229,9502,3665,1980
31 Dec 218,848-2,2395,2340
30 Sep 212,865-9,5823,9090
30 Jun 213,415-7,4083,7530
31 Mar 213,780-7,4493,6090
31 Dec 205,207-6,7303,6250
30 Sep 205,754-6,4454,9064
30 Jun 206,017-8,5304,8744
31 Mar 207,082-7,3024,95134
31 Dec 197,378-8,2105,359152
31 Dec 1420,672-1,6165,398357
30 Sep 1420,7592233,427335
30 Jun 1420,298913,357348
31 Mar 1420,6985083,044349
31 Dec 1321,4331652,724381

Quality Earnings: A043090 is currently unprofitable.

Growing Profit Margin: A043090 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: A043090 is unprofitable, and losses have increased over the past 5 years at a rate of 31.1% per year.

Accelerating Growth: Unable to compare A043090's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A043090 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (18%).


Return on Equity

High ROE: A043090 has a negative Return on Equity (-41.44%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies